Rewriting the prognosis of multiple sclerosis in Brazil: a 25-year perspective on evolving diagnostic criteria.
作者信息
Callegaro Dagoberto, Silva Guilherme Diogo
机构信息
Universidade de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil.
出版信息
Arq Neuropsiquiatr. 2025 Jun;83(6):1-2. doi: 10.1055/s-0045-1809937. Epub 2025 Jul 2.
Abstract
摘要
相似文献
1
Rewriting the prognosis of multiple sclerosis in Brazil: a 25-year perspective on evolving diagnostic criteria.改写巴西多发性硬化症的预后：对不断演变的诊断标准的25年展望。
Arq Neuropsiquiatr. 2025 Jun;83(6):1-2. doi: 10.1055/s-0045-1809937. Epub 2025 Jul 2.
2
The impact of changing diagnostic criteria on disability in a Brazilian multiple sclerosis cohort.诊断标准的变化对巴西多发性硬化症队列中残疾状况的影响。
Arq Neuropsiquiatr. 2025 Jun;83(6):1-9. doi: 10.1055/s-0045-1809662. Epub 2025 Jun 25.
3
Overall prognosis of preschool autism spectrum disorder diagnoses.学龄前自闭症谱系障碍诊断的总体预后。
Cochrane Database Syst Rev. 2022 Sep 28;9(9):CD012749. doi: 10.1002/14651858.CD012749.pub2.
4
Azathioprine for people with multiple sclerosis.硫唑嘌呤用于多发性硬化症患者。
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
5
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.对首次出现提示多发性硬化症临床发作的患者使用疾病修饰药物进行治疗。
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2.
6
Prevalence of multiple sclerosis in Brazil: An updated systematic review with meta-analysis.巴西多发性硬化症的患病率：一项更新的系统评价与荟萃分析。
Clin Neurol Neurosurg. 2025 Feb;249:108741. doi: 10.1016/j.clineuro.2025.108741. Epub 2025 Jan 13.
7
Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand.新西兰社会与医疗保健视角下奥瑞珠单抗治疗原发性进行性多发性硬化症的成本效益分析
Pharmacoeconomics. 2025 May 7. doi: 10.1007/s40273-025-01486-z.
8
Longitudinally extensive transverse myelitis: Impact on functional prognosis and mortality in a 10-year follow-up cohort.纵向广泛横贯性脊髓炎：10年随访队列中对功能预后和死亡率的影响
Mult Scler Relat Disord. 2025 Feb;94:106279. doi: 10.1016/j.msard.2025.106279. Epub 2025 Jan 20.
9
Artificial intelligence in the diagnosis of multiple sclerosis: A systematic review.人工智能在多发性硬化症诊断中的应用：一项系统评价。
Mult Scler Relat Disord. 2022 Mar;59:103673. doi: 10.1016/j.msard.2022.103673. Epub 2022 Feb 7.
10
Ocrelizumab for multiple sclerosis.奥瑞珠单抗治疗多发性硬化症。
Cochrane Database Syst Rev. 2022 May 18;5(5):CD013247. doi: 10.1002/14651858.CD013247.pub2.
本文引用的文献
1
The impact of changing diagnostic criteria on disability in a Brazilian multiple sclerosis cohort.诊断标准的变化对巴西多发性硬化症队列中残疾状况的影响。
Arq Neuropsiquiatr. 2025 Jun;83(6):1-9. doi: 10.1055/s-0045-1809662. Epub 2025 Jun 25.
2
The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil.导致多发性硬化症治疗惰性的误区：巴西高效药物的成本效益分析
Arq Neuropsiquiatr. 2024 Jan;82(1):1-2. doi: 10.1055/s-0044-1779036. Epub 2024 Feb 5.
3
Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process-Cohort study.巴西参考中心多发性硬化症的误诊：临床、影像学、实验室特征及诊断过程中的失误-队列研究。
Mult Scler. 2023 Dec;29(14):1755-1764. doi: 10.1177/13524585231199323. Epub 2023 Oct 3.
4
Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis.2022 年首次视神经炎发作的诊断标准在真实世界中的应用。
J Neuroimmunol. 2023 Aug 15;381:578140. doi: 10.1016/j.jneuroim.2023.578140. Epub 2023 Jun 20.
5
Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis.多发性硬化症早期强化治疗与逐步升级治疗策略的成本、疗效及安全性比较：一项系统评价与荟萃分析
Mult Scler Relat Disord. 2023 Mar;71:104581. doi: 10.1016/j.msard.2023.104581. Epub 2023 Feb 16.
6
Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in São Paulo, Brazil.巴西圣保罗的水通道蛋白 4 阳性视神经脊髓炎谱系障碍和髓鞘少突胶质细胞糖蛋白抗体相关疾病的估计患病率。
Mult Scler Relat Disord. 2023 Feb;70:104488. doi: 10.1016/j.msard.2022.104488. Epub 2022 Dec 23.
7
Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center's approach.降低多发性硬化症和视神经脊髓炎谱系疾病的感染风险：巴西参考中心的方法。
Arq Neuropsiquiatr. 2022 Oct;80(10):1057-1066. doi: 10.1055/s-0042-1754348. Epub 2022 Oct 4.
8
Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.在进展性多发性硬化症中，超适应证使用高效疾病修正药物是否有作用？一项网络荟萃分析。
Acta Neurol Scand. 2022 Nov;146(5):403-409. doi: 10.1111/ane.13697. Epub 2022 Sep 2.
9
Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system.巴西神经病学学会神经免疫学科学部（DCNI/ABN）以及巴西多发性硬化症和神经免疫疾病治疗与研究委员会（BCTRIMS）关于一般疫苗接种，特别是针对中枢神经系统脱髓鞘疾病患者接种新型冠状病毒2（SARS-CoV-2）疫苗的建议。
Arq Neuropsiquiatr. 2021 Nov;79(11):1049-1061. doi: 10.1590/0004-282X-ANP-2021-0162.
Zotero 插件